Table 9.
Reasons why patients with bone metastases/lesions would never receive bisphosphonates, by malignancy type and by country: data from the detailed questionnaire
| Reason given (%) | Total (N = 1360) | France (n = 250) | Germany (n = 304) | Italy (n = 226) | Spain (n = 216) | UK (n = 364) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | |
| Renal issue | 36 | 39 | 46 | 21 | 55 | 66 | 34 | 59 | 33 | 32 | 18 | 22 |
| Dental health issue | 9 | 10 | 9 | 8 | 20 | 12 | 9 | 15 | 3 | 12 | 2 | 1 |
| Poor benefit–risk ratio | 34 | 31 | 43 | 40 | 29 | 23 | 38 | 21 | 25 | 28 | 36 | 42 |
| Patient refusal | 6 | 3 | 7 | 2 | 10 | 2 | 6 | 8 | 4 | 0 | 5 | 5 |
| Short life expectancy | 41 | 21 | 38 | 13 | 41 | 14 | 32 | 17 | 52 | 42 | 41 | 22 |
| Pain from BM controlled by analgesics/opioids | 14 | 11 | 19 | 21 | 14 | 12 | 8 | 4 | 9 | 5 | 18 | 4 |
| Other | 5 | 17 | 7 | 35 | 3 | 17 | 5 | 18 | 9 | 10 | 4 | 0 |
BM, bone metastases/lesions; HM, haematological malignancy; ST, solid tumour.
Investigators could give more than one response.